Last reviewed · How we verify
AKR-963
AKR-963 is a selective agonist of the adenosine A1 receptor that modulates immune and inflammatory responses.
AKR-963 is a selective agonist of the adenosine A1 receptor that modulates immune and inflammatory responses. Used for Inflammatory and immune-mediated disorders (specific indication under investigation in Phase 3).
At a glance
| Generic name | AKR-963 |
|---|---|
| Sponsor | Trygg Pharma, Inc. |
| Drug class | Adenosine A1 receptor agonist |
| Target | Adenosine A1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
AKR-963 selectively activates adenosine A1 receptors, which are G-protein coupled receptors involved in immunoregulation and inflammation control. By engaging this pathway, the drug is designed to suppress excessive immune activation and reduce inflammatory signaling in disease states. This mechanism is being explored for conditions where immune modulation could provide therapeutic benefit.
Approved indications
- Inflammatory and immune-mediated disorders (specific indication under investigation in Phase 3)
Common side effects
- Bradycardia
- AV conduction delays
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |